Does Rallies show 13F holders for PACB?

Yes. Rallies tracks hedge fund and 13F ownership data for PACB, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PACB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PACB. It does not provide personalized investment advice.

PACB (Pacific Biosciences of California, Inc.) Stock Analysis - Hedge Fund Holdings

Pacific Biosciences of California, Inc. (PACB) is a publicly traded Healthcare sector company. As of May 21, 2026, PACB trades at $1.22 with a market cap of $357.19M and a P/E ratio of -2.71. PACB moved +3.91% today. Year to date, PACB is -39.90%; over the trailing twelve months it is +16.67%. Its 52-week range spans $0.85 to $2.73. Analyst consensus is neutral with an average price target of $2.38. Rallies surfaces PACB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PACB stock?

Hedge funds tracked by Rallies that own PACB include Soros Fund, Panagora Asset, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pacific Biosciences of California, Inc..

PACB Key Metrics

Key financial metrics for PACB
Metric	Value
Price	$1.22
Market Cap	$357.19M
P/E Ratio	-2.71
EPS	$-0.43
Dividend Yield	0.00%
52-Week High	$2.73
52-Week Low	$0.85
Volume	9.14K
Avg Volume	0
Revenue (TTM)	$160.03M
Net Income	$-128.58M
Gross Margin	37.49%

Top Hedge Funds Holding PACB

Soros Fund holds 1.00M shares of PACB, changed -57.85% as of Mar 31, 2025.
Panagora Asset holds 502.66K shares of PACB, changed +0.00% as of Mar 31, 2026.
Polen Capital holds 137.15K shares of PACB, changed +0.00% as of Dec 31, 2025.
Farallon Capital holds 135.00K shares of PACB, changed +0.00% as of Mar 31, 2026.

Latest PACB News

PacBio HiFi Sequencing Identifies Genetic Causes in ~10% of Subfertile Couples — May 11, 2026
Pacific Biosciences Posts $0.12 Q1 Loss, Revenues Miss Estimates — May 7, 2026
PacBio Integrates Lucid Genomics for Streamlined HiFi Sequencing Analysis — Apr 21, 2026
PacBio, Covaris Launch FFPE Workflow Yielding 100M HiFi Reads and 5,000bp Fragments — Apr 15, 2026
PacBio Powers Trillion Gene Atlas with HiFi Sequencing for 100,000 Samples — Mar 18, 2026

Recent PACB Insider Trades

Gibson James R II sold 88.19K (~$120.81K) on Apr 1, 2026.
HENRY CHRISTIAN O sold 12.50K (~$18.92K) on Mar 3, 2026.
Van Oene Mark sold 6.50K (~$9.85K) on Mar 3, 2026.

PACB Analyst Consensus

4 analysts cover PACB: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.38.

Common questions about PACB

Who owns PACB stock?: Hedge funds tracked by Rallies that own PACB include Soros Fund, Panagora Asset, Polen Capital, and Farallon Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pacific Biosciences of California, Inc..
Does Rallies show 13F holders for PACB?: Yes. Rallies tracks hedge fund and 13F ownership data for PACB, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PACB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PACB. It does not provide personalized investment advice.